Ramipril Shortage UK 2026: SSP087 Ended 30 October. Is Supply Back Yet?

Current Shortage Status: SSP087 and MSN/2026/043

SSP087, the Serious Shortage Protocol for ramipril 1.25mg capsules, has ended. The NHSBSA (NHS Business Services Authority) lists it as running from 22 April 2026 to 30 October 2026 (amended 23 July 2026), and it has not been extended (checked 1 November 2026). Community Pharmacy England reported DHSC's confirmation that SSP087 expired at 23:59 on 30 October 2026, and that prescriptions for ramipril 1.25mg capsules must now be dispensed in accordance with the prescription. While it ran, it was a quantity SSP: where a prescription asked for more than a month, the pharmacist could supply one month's worth. It never authorised a switch to another medicine. Separately, DHSC's MSN/2026/043 said all four ramipril capsule strengths were in limited supply until the end of October 2026. That date has passed, and DHSC has not issued an update or said supply is back. The notice says ramipril tablets remain available but cannot support extra demand, and DHSC does not recommend routine switching to other ACE inhibitors or ARBs. Check the ramipril status page for any new notice.

What Is Ramipril and Who Takes It?

Ramipril is an ACE inhibitor — a class of medicine that works by blocking an enzyme (angiotensin-converting enzyme) that causes blood vessels to narrow. By relaxing blood vessels, ramipril reduces blood pressure and makes it easier for the heart to pump blood around the body.

Ramipril is one of the most widely prescribed medicines in the UK. An estimated 5–6 million people in England take an ACE inhibitor, with ramipril being the most commonly used in this class.

Common uses of ramipril

The clinical importance of ramipril means any shortage needs to be managed carefully. For many patients — especially those with heart failure or following a heart attack — stopping or changing their ACE inhibitor without medical guidance could carry real health risks.

What Is a Serious Shortage Protocol?

A Serious Shortage Protocol (SSP) is a legal mechanism introduced in 2019 that gives pharmacists specific powers during medicine shortages. Understanding what an SSP means in practice is important if you are affected by the ramipril shortage.

What an SSP allows pharmacists to do

Under an active SSP, a pharmacist can dispense a specified alternative medicine without requiring you to get a new prescription from your GP. The SSP defines exactly which alternative(s) can be supplied. The pharmacist is responsible for:

• Confirming the alternative is clinically appropriate for you
• Explaining what the alternative is and how to take it
• Documenting the supply on your patient record
• Counselling you on any differences from your usual medicine

What an SSP does NOT mean

• It does not mean your pharmacist can give you any medicine they choose — the SSP specifies the permitted alternatives
• It does not bypass your pharmacist's clinical judgement — they can decline to apply the SSP if it is not appropriate for you
• It does not replace the need to inform your GP — your pharmacist should notify your GP of the switch

How long does an SSP last?

SSPs are issued for a defined period and are extended if supply does not recover. For ramipril, SSP071 (2.5mg tablets) ran from 6 August to 29 November 2024 and has ended. SSP087 (1.25mg capsules) ran from 22 April to 30 October 2026, was amended on 23 July 2026, and ended on 30 October without an extension. The NHSBSA reviews active SSPs regularly and can extend them, withdraw them early or let them end, so check the ramipril status page for the current position.

Why Is 2.5mg Specifically Affected?

The 2.5mg strength of ramipril is the starting (titration) dose — the lowest available strength, used when initiating treatment. Here is why it is disproportionately affected:

It's the starting dose for new patients

Clinical guidelines recommend starting ramipril at 1.25mg or 2.5mg for most indications, then titrating up over weeks or months based on blood pressure response and tolerability. The 2.5mg dose is therefore used by two groups: patients who have just started ramipril and are on a low dose, and long-term patients who have settled at 2.5mg as their optimal dose.

Production volumes and margins

Lower-strength formulations often have a smaller market than the 5mg or 10mg versions. With thinner margins across all generic medicines, manufacturers may prioritise higher-volume, higher-revenue strengths when capacity is constrained. The 2.5mg strength is simply more vulnerable in this environment.

Harder to substitute within the same drug

A patient on ramipril 10mg could, in theory, take half a 20mg tablet (if such existed) — though this is not standard practice. A patient on 2.5mg cannot easily split a 5mg tablet to get 2.5mg because splitting unscored tablets is not recommended without specific guidance. This makes the 2.5mg strength functionally irreplaceable without switching to an alternative medicine.

Why Is Ramipril In Shortage?

The structural factors behind the ramipril shortage are similar to those affecting many generic medicines in the UK:

Generic medicine economics

Ramipril is a well-established generic medicine — its patent expired decades ago. This means multiple manufacturers compete on price, driving down margins. When margins are thin, investment in production resilience, safety stock, and manufacturing capacity is limited. A single manufacturing disruption can quickly lead to a nationwide shortage.

Concentrated manufacturing base

Despite the global generic market being large, actual production of ramipril API (active pharmaceutical ingredient) is concentrated in a small number of manufacturing sites, predominantly in India and China. Regulatory actions, quality issues, or logistics problems at any of these sites can cascade into UK supply disruptions.

Demand growth

The UK has seen sustained growth in prescribing of cardiovascular medicines as the population ages and NHS cardiovascular prevention programmes identify and treat more patients. This growing demand, combined with any supply constraint, tips the balance towards shortage.

Post-COVID logistics

Global pharmaceutical supply chains have not fully recovered from the disruptions of 2020-2022. Shipping delays, increased costs, and raw material volatility continue to affect the availability of generic medicines.

Alternative ACE Inhibitors

ACE inhibitors work through the same mechanism and are generally interchangeable for most indications, though individual responses may vary. No current protocol lets a pharmacist switch you to one of these (SSP087, which ended on 30 October 2026, never did), and DHSC (MSN/2026/043) advises against routine switching because their supply could be stretched. If your GP or prescriber decides a change is needed, these are the ACE inhibitors they may consider:

Alternative ARBs (Angiotensin Receptor Blockers)

If you are unable to tolerate ACE inhibitors (for example, due to a persistent dry cough, which affects around 10-15% of ACE inhibitor users), an ARB may be considered. ARBs block the same renin-angiotensin system at a different point and have similar blood pressure and organ-protective effects. They are generally better tolerated but historically slightly more expensive.

What Patients Should Do Right Now

If you take ramipril (capsules or tablets) and are having difficulty obtaining your prescription:

• Visit your pharmacy and explain the supply issue — ask the pharmacist what they can supply against your prescription. SSP087 ended on 30 October 2026, so it no longer limits ramipril 1.25mg capsules to one month at a time, but stock may still be short, so reorder early
• Your pharmacist cannot switch you to a different medicine without a new prescription — a change of medicine, or from capsules to tablets, needs a new prescription from your GP or prescriber, so ask early
• If your pharmacist cannot help, try another local pharmacy — stock levels vary
• Contact your GP if you want to discuss alternatives or if your pharmacist is unable to resolve the issue
• Do not stop taking your blood pressure medicine suddenly — this can cause blood pressure to rise sharply
• Keep a note of your blood pressure readings during any transition — a home blood pressure monitor is useful
• Sign up for MediWatch alerts to be notified when ramipril's shortage status changes

If you take ramipril for heart failure or post-heart attack

If your ramipril has been prescribed specifically for heart failure or following a myocardial infarction, your situation may be more complex than simple hypertension management. Do not wait for the SSP process alone — contact your GP or cardiology team directly to ensure any transition is appropriately managed. The stakes are higher in these scenarios.

Managing Blood Pressure During Medicine Shortages

A short gap in blood pressure treatment can cause your blood pressure to rise. While a brief interruption is unlikely to cause immediate harm for most people, ongoing periods of uncontrolled hypertension increase the risk of stroke, heart attack, and kidney damage.

Practical steps while your supply is disrupted

• Monitor at home: If you have a home blood pressure monitor (available from most pharmacies), take readings regularly during any transition. Aim for below 130/80 mmHg if possible.
• Lifestyle measures: During any gap in medication, attention to salt intake, alcohol consumption, physical activity, and weight management can help stabilise blood pressure.
• Stay in contact with your GP: If your readings are consistently above 140/90 mmHg without medication, let your GP know.
• Don't panic over one high reading: Blood pressure naturally varies — a single high reading after missing a dose is common. It's patterns over time that matter.

Frequently Asked Questions

Related Medicine Shortages